RESEARCH ARTICLE Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro- inflammatory activity associated to the portal vein endothelium of cirrhotic rats Jordi Ribera1☯, Juan Rodrı́guez-Vita1,2☯, Bernat Cordoba1, Irene Portolés1, Gregori Casals1, Eudald Casals3, Wladimiro Jiménez1,4, Victor Puntes3, Manuel Morales- Ruiz ID1,4* a1111111111 1 Biochemistry and Molecular Genetics Department, Hospital Clı́nic of Barcelona, Institut d’Investigacions a1111111111 Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red de Enfermedades a1111111111 Hepáticas y Digestivas (CIBERehd), Barcelona, Spain, 2 German Cancer Research Center, Heidelberg, a1111111111 Germany, 3 Catalan Institute of Nanotechnology (ICN), Bellaterra, Spain, 4 Department of Biomedicine- a1111111111 Biochemistry Unit, School of Medicine University of Barcelona, Barcelona, Spain ☯ These authors contributed equally to this work. * morales@clinic.ub.es OPEN ACCESS Citation: Ribera J, Rodrı́guez-Vita J, Cordoba B, Abstract Portolés I, Casals G, Casals E, et al. (2019) Functionalized cerium oxide nanoparticles mitigate the oxidative stress and pro-inflammatory activity Background and aims associated to the portal vein endothelium of cirrhotic rats. PLoS ONE 14(6): e0218716. https:// The occurrence of endothelial alterations in the liver and in the splanchnic vasculature of cir- doi.org/10.1371/journal.pone.0218716 rhotic patients and experimental models of liver diseases has been demonstrated. However, Editor: Matias A. Avila, University of Navarra the pathological role of the portal vein endothelium in this clinical context is scarcely studied School of Medicine and Center for Applied Medical and, therefore, deserves attention. In this context, we aimed to investigate whether patho- Research (CIMA), SPAIN logical endothelial activation occurs in the portal vein of cirrhotic rats. Received: April 26, 2019 Accepted: June 7, 2019 Methods Published: June 24, 2019 Cirrhosis was induced in wistar rats by CCl4 inhalation. We generated immortalized endo- thelial cells from the portal vein of control (CT-iPVEC) and cirrhotic rats (CH-iPVEC) by ret- Copyright: © 2019 Ribera et al. This is an open access article distributed under the terms of the roviral transduction of the SV40 T antigen. We assessed differential gene expression and Creative Commons Attribution License, which intracellular reactive oxygen species (ROS) levels in iPVECs and in portal veins of control permits unrestricted use, distribution, and and cirrhotic rats. Finally, we assessed the therapeutic effectiveness of cerium oxide nano- reproduction in any medium, provided the original particles (CeO2NP) on reversing PVEC activation and macrophage polarization. author and source are credited. Data Availability Statement: All relevant data are within the manuscript and its Supporting Results Information files. CH-iPVECs overexpressed collagen-I, endothelin-1, TIMP-1, TIMP-2, IL-6 and PlGF genes. Funding: Supported by grants from the Ministerio These results were consistent with the differential expression showed by whole portal veins de Economı́a y Competitividad (SAF 2015-64126-R from cirrhotic rats. In addition, CH-iPVECs showed a significant increase in intracellular to WJ, PI15-00077 to GC and SAF2016-75358-R ROS and the capacity of potentiating M1 polarization in macrophages. The treatment of CH- to MM-R), co-financed by FEDER, European Union, a way of making Europe, Fundació La Marató de iPVECs with CeO2NPs blocked intracellular ROS formation and IL-6 and TIMP-2 gene over- TV3 (Marató 120930), Spanish MINECO expression. In agreement with the in vitro results, the chronic treatment of cirrhotic rats with PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 1 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats (MAT2015-70725-R) and the Catalan Agència de CeO2NPs also resulted in the blockade of both ROS formation and IL-6 gene overexpres- Gestió d’Ajuts Universitaris i de Recerca (AGAUR) sion in whole portal veins. (2017-SGR-143 to VP and 2016-BP-00301 to EC). JR-V is the recipient of a BIOTRACK Postdoctoral Fellowship supported by the European Conclusions Community’s Seventh Framework Programme and Endothelial cells from portal vein of cirrhotic rats depicted an abnormal phenotype charac- the MINECO (Contract 229673). CIBERehd is terized by a differential gene expression and the induction of M1 polarization in macro- financed by the Instituto de Salud Carlos III. The funders had no role in study design, data collection phages. We identified the excess of intracellular reactive oxygen species (ROS) as a major and analysis, decision to publish, or preparation of contributor to this altered phenotype. In addition, we demonstrated the utility of the nanoma- the manuscript. terial cerium oxide as an effective antioxidant capable of reverse some of these pathological Competing interests: The authors have declared features associated with the portal vein in the cirrhosis condition. that no competing interests exist. Introduction The portal vein carries blood from the gastrointestinal track to the liver contributing to the ~70% of the hepatic blood volume. This anatomical arrangement causes that the concentra- tions of certain hormones, metabolites and in some cases toxics xenobiotics are comparatively higher in the hepatic portal circulation than in any other vascular territory [1,2]. The exposure of the portal vein to this portal circulatory environment may result in the vascular activation of proinflammatory immune modulators that eventually may contribute to the development or worsening of portal hypertensive syndromes. For instance, the diseases most commonly encountered in the group of non-cirrhotic portal hypertensive syndromes are idiopathic portal hypertension and extrahepatic portal vein thrombosis and although the etiology of both pathologies are unclear it is considered to be pre-hepatic and vascular in origin with a signifi- cant pro-inflammatory component [3,4]. The pathological role of the portal vein in cirrhotic portal hypertensive syndromes has also been described in some contexts such as alcoholic cir- rhosis. The resistance to portal blood flow in these patients is predominantly sinusoidal, but vascular remodeling of the portal vein also contribute to the overall intrahepatic resistance [5,6]. Based on these observations, we hypothesized that alterations in the functional properties of the portal vein may occur in portal hypertensive syndrome and that the pathophysiological characterization of this vascular bed is clinically relevant. A normofunctional endothelium is crucial for the maintenance of vascular integrity through its anti-coagulant, anti-inflammatory and vasodilatory properties. However, several studies showed that the vascular endothelium may change to an activated/dysfunctional phe- notype characterized by its pro-coagulant, pro-inflammatory and vasoconstrictive properties [7–11]. Endothelial cell activation has been documented in liver sinusoids in the context of chronic liver diseases [12–17]. However, very few publications have investigated the pathologi- cal role of the endothelial cell activation in other vascular areas such as the portal vein. A key limitation of this research field is the lack of established cell lines and the low-throughput char- acteristics of the classical cell isolation methods used to isolate endothelial cells from this vas- cular territory. In our study, we overcome this limitation by isolating primary endothelial cells from the portal vein of control and cirrhotic rats and immortalizing them by retroviral trans- duction of the SV40 large T antigen (iPVEC). The objectives of our study were 1) to character- ize the differential phenotype of iPVECs after the establishment of these cell lines, 2) to correlate the cellular in vitro findings with the in vivo abnormalities of the portal vein in con- trol and in cirrhotic rats and 3) to identify key molecular mechanisms responsible for switch- ing the endothelium of the portal vein from a normofunctional to a dysfunctional state. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 2 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Here we show that endothelial cells from portal vein of CH rats depicted an abnormal phe- notype characterized by a differential gene expression of proinflammatory, vasoactive and extracellular matrix remodeling genes. In addition, these cells showed a differential secretome and the capacity of potentiating M1 polarization in macrophages. We identified intracellular oxidative stress as a major contributor to this altered phenotype and evaluated the therapeutic utility of cerium oxide nanoparticles to revert the abnormalities found in the portal vein endo- thelium of cirrhotic rats. Materials and methods Experimental model of fibrotic rats This study was performed in male adult Wistar rats with liver fibrosis (CCl4-treated rats) and control (CT) Wistar rats (Charles–River, Saint Aubin les Elseuf, France). Liver fibrosis was induced by inhalation of CCl4, as has previously been described [18]. All the animals were housed in 595×380×200 mm cages (Techniplast UK, 1354G Eurostandard Type IV) and were kept under constant temperature and humidity in a 12-h controlled dark/light cycle. The rats were fed ad libitum on a standard pellet diet. Control rats and CCl4-treated rats were studied 20 weeks after the start of the fibrosis induction protocol. During housing, animals were moni- tored twice daily for health status. No adverse events were observed. All animal procedures were approved by the Investigation and Ethics Committee of Animal Experimentation of the University of Barcelona. Isolation and immortalization of PVECs Portal veins were isolated and digested with a 0.25% solution of collagenase A (Roche, Mann- heim, Germany). Primary PVECs were isolated from the portal vein of control and cirrhotic (CH) rats using a rabbit anti-rat CD31 antibody (Abbiotec, San Diego, CA, USA) and mag- netic beads coupled with a goat anti-rabbit secondary antibody (MACS system, Miltenyi Bio- tec, Germany). The immortalization of the endothelial cells was performed when the cells reached 75% of confluence by retroviral transduction of the middle T antigen from the SV40 virus and a geneticin resistance gene. After retroviral transduction, cells were maintained in Endothelial Cell Growth Medium 2 (Promocell, Heidelberg, Germany) supplemented with 50 U/mL penicillin, 50 μg/mL streptomycin and 10% fetal calf serum (FBS). Flow cytometry Purity of endothelial cells was assessed by flow cytometry. First, cells were washed and re-sus- pended in PBS supplemented with 5% heat-inactivated FBS. A rabbit anti-rat CD31 (Abbiotec, San Diego, CA, USA) was used as a primary antibody. Then, cells were labeled using Alexa- 488 conjugated anti-Rabbit secondary antibody (Life Technologies, Carlsbad, CA, USA). Posi- tive cells were detected on a FACSCanto II flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed using FACSdiva software (BD Biosciences, San Jose, CA, USA). The nega- tive population for the CD31 antigen was chosen from cells quantified in the absence of anti- CD31 antibody. Characterization and quantification of CeO2NP CeO2NPs, with an average diameter of 4–20 nm, were synthesized by the chemical precipita- tion of cerium (III) nitrate hexahydrated (Sigma-Aldrich, St. Louis, MO, USA) as previously described [19,20]. High resolution Transmission Electron Microscopy (HR-TEM) was per- formed using a JEOL-1010 TEM (JEOL, Tokyo, Japan) with the field-emission gun operating PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 3 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats at 80 kV. Prior to the analysis, 15μL from the nanoparticles solution were dispersed on a cop- per grid coated with a formvar film. The samples were then let to dry for TEM observation and digital photomicrographs were taken (BioScan Gatan, CA, USA). Cerium concentration in tis- sue was measured by inductively coupled plasma mass spectrometry (ICP-MS, Agilent 7500; Agilent Technologies CA, USA). The quantification is performed by interpolation in a stan- dard curve obtained from a commercial 1000 ppm Ce standard (Sigma-Aldrich, St. Louis, Mis- suori, USA). In vivo and in vitro studies with CeO2NPs treatment For the in vivo study, control and cirrhotic rats were randomly distributed into two groups. One group was treated with 0.1 mg/kg of CeO2NPs in TmaOH 0.8mM (n = 20 for each experi- mental condition) and CCl4 treatment was maintained thereafter. The second group received vehicle (saline solution containing TMAOH ammonium salts 0.8 mM) (n = 20 for each experi- mental condition). CeO2NPs were dispersed in saline solution and intravenously given as a bolus (500 μL) through the tail vein. For the intravenous injection, animals were initially anaesthetized under a 5% of isoflurane inhalation and then maintained under 2–2.5% isoflur- ane for the rest of the procedure, with an oxygen flow rate of 800 cc/min. The treatments were administered twice per week for two weeks. At the end of the treatments, rats were euthanized by anaesthesia overdose (5% of isoflurane inhalation in oxygen) and organs dissected and kept at -80 ºC for further analysis. For the in vitro study, cells were treated with CeO2NPs (1μg/mL) for 24 hours in a water- jacketed CO2 incubator (Forma Scientific Series II, 3131, Marietta, OH). Scanning electron microscope (SEM) Portal vein samples were fixed in 2% paraformaldehyde and 2.5% gluteraldehyde for further ultrastructural examination. Next, each sample was ion-sputter-coated and observed at low electron power microscope to increase contrast in a Jeol JSM 5600 LV scanning electron microscope (Jeol Ltd., Tokyo, Japan) equipped with a BioScan camera (Gatan, CA, USA), and digital photomicrographs were taken. Macrophage differentiation Briefly, femurs from rats aged 8 to 10 weeks were flushed and bone marrow derived cells were collected by centrifugation at 450×g for 5 min at 4˚C. Cells were then re-suspended in DMEM, supplemented with 10% heat-inactivated FBS and 30% of L-929 M-CSF conditioned medium, and cultured at a density of 1×106 cells/mL in non-tissue culture treated plastic dishes (BD Bio- sciences, San Jose, CA, USA) in a humidified atmosphere (95% air, 5%CO2) at 37˚C. Medium was replaced every 2 days. After 6 days, adherent cells were collected and cell viability was mea- sured by trypan blue. Bone marrow derived macrophages (BMDM) were then diluted in DMEM containing 10% of heat-inactivated FBS and plated in culture dishes for further experiments. Generation of M-CSF containing conditioned medium M-CSF overexpressing L929 cells were kindly donated by Prof. Antonio Celada (Macrophage Biology Group, School of Biology-University of Barcelona). Cells were cultured up to a 75% of confluence in DMEM supplemented with 2% of heat-inactivated FBS, 50 U/ml penicillin and 50 μg/ml streptomycin. After 5 days of culturing, medium was replaced keeping the collected medium. On the tenth day, the medium was collected and mixed with the conditioned PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 4 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats medium obtained at day 5. After filtration with a 0.2 μm filter, the final conditioned medium was stored at -20ºC for later use. The concentration of M-CSF in this conditioned medium was 5 ng/mL, according to ELISA quantification (Cusabio, Baltimore, MD, USA). Immunocytofluorescence The iPVECs were fixed with 4% paraformaldehyde for 10 minutes. Cells were washed three times with PBS and permeabilized with 0.1% Triton for 4 minutes at 4˚C. Then, cells were incubated for 1 hour with rabbit anti-rat CD31 primary antibody (Abbiotec, San Diego, CA, USA) and anti-rabbit FITC secondary antibody (Life Technologies, Carlsbad, CA, USA) for 1 h. Immunofluorescence was visualized with a fluorescent microscope (Nikon Eclipse E600, Kawasaki, Kanagawa, Japan). Real-Time PCR Total RNA was extracted from cultured PVEC using the Trizol reagent (Life Technologies, Carlsbad, CA, USA). One microgram of total RNA was reverse transcribed using First Strand cDNA Synthesis Kit (Roche, Mannheim, Germany). Subsequently, complementary DNA sam- ples were amplified for 30–35 cycles (94 for 30 seconds, 55–60˚C for 30 seconds, and 72 during 1 minute; LigthCycler 480-Roche Diagnostics). To normalize the results, HPRT gene was used as reference. Specific primers for amplification of the complementary DNA were: Collagen I, 5'-AGACCTGGCGAGAGAGGAGT-3' (forward primer) and 5'-ATCCAGAC CGTTGTGTCCTC-3' (reverse primer); TIMP1, 5’-CATGGAGAGCCTCTGTGGAT-3' (forward primer) and 5'-TGTGCAAATTT CCGTTCCTT-3' (reverse primer); TIMP2, 5’-GACAAGGACATCGAATTTATCTACAC-3' (forward primer) and 5'-CCATC TCCTTCCGCCTTC-3' (reverse primer); PlGF, 5’-GTTGGCTGTGCACTCCCAG-3' (forward primer) and 5'-GTTGGCTGTGCAC TCCCAG-3' (reverse primer); Endothelin-1, 5'-CTCCTCCTTGATGGACAAGG-3' (forward primer) and 5'-CTTGATG CTGTTGCTGATGG-3' (reverse primer); IL-6, 5'-GCCCTTCAGGAACAGCTATGA-3' (forward primer) and 5'-TGTCAACAACAT CAGTCCCAAGA-3' (reverse primer); MMP2, 5’-GCGCTTTTCTCGAATCCAT-3' (forward primer) and 5'-GGGTATCCATCT CCATGCTC-3' (reverse primer); eNOS, 5’-TCTACCGGGACGAGGTACTG-3' (forward primer) and 5'-CTGTCCTCAGG AGGTCTTGC-3' (reverse primer); iNOS, 5’-ACAACAGGAACCTACCAGCTCA-3' (forward primer) and 5'-GATGTTGTAG CGCTGTGTGTCA-3' (reverse primer); TNF-α, 5’-CAAGGAGGAGAAGTTCCCAA-3' (forward primer) and 5'-CTCTGCTTGGT GGTTTGCTA-3' (reverse primer); Arginase-1, 5’-CAAGCTGGGAATTGGCAAAG-3' (forward primer) and 5'-GGTCCAGT CCATCAACATCAAA-3' (reverse primer); and HPRT, 5’-GACCGGTTCTGTCATGTCG-3' (forward primer) and 5'-ACCTGGTTCATC ATCACTAATCAC-3' (reverse primer). Characterization of iPVEC secretome by mass spectrometry Protein profiling was performed by surface-enhanced laser desorption/ionization time-of- flight mass spectrometry (SELDI-TOF-MS) using the eight-spot format CM10 ProteinChip arrays (Bio-Rad, Hercules, CA, USA). Conditioned cell culture media from iPVECs was loaded PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 5 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats onto CM10 Protein Chip arrays. Prior to sample loading, spots were equilibrated two times with 200 μL of CM binding/washing buffer (0.1 M sodium acetate, pH 4). Each sample was loaded in duplicate randomly in order to minimize any systematic error. Forty microliters of conditioned medium were incubated in 60 μL of CM binding buffer for 30 minutes on a shaker at room temperature. Afterwards, arrays were washed three times with 200 μL CM washing buffer for 5 minutes at room temperature. Unbound serum proteins were removed by washing twice with deionized water. Thereafter, arrays were air-dried and 1 μL of energy- absorbing matrix (saturated sinapinic acid in an aqueous solution containing 50% acetonitrile and 0.5% TFA) was added twice to each spot. The surface was allowed to air dry between each application. The array was read by using the ProteinChip PBS II reader (BioRad, Hercules, CA, USA). Each spot was read at 3000 nJ energy laser intensity. All spectra were calibrated using two external calibration standards (all-in-one peptide standard and all-in-one protein standard, BioRad, Hercules, USA). A peak resolution was optimized within 5.000 m/z, 12.000 m/z or 19.000 m/z according to low, medium or high energy laser intensity, respectively. Western blot experiments Cell lysates were prepared in a lysis buffer (Tris–HCl 20 mM pH 7.4 containing 1% Triton X- 100, 0.1% SDS, 50 mM NaCl, 2.5 mM EDTA, 1 mM Na4P2O7 10H2O, 20 mM NaF, 1 mM Na3VO4, 2 mM Pefabloc and Complete from Roche). Proteins were separated on a 7.5% SDS- polyacrylamide gel (Mini Protean III, BioRad, Richmond, Ca) and transferred for 2 hours at 4ºC to nitrocellulose membrane (Transblot Transfer Medium, BioRad, Richmond, CA) that was stained with Ponceau-S red as a control for protein loading. The membrane were incu- bated at 4ºC with rabbit polyclonal anti-rat VE-Cadherin (Abcam plc, Cambridge, UK) over- night in a 1:1000 dilution. Then, the membrane was incubated with goat anti-rabbit peroxidase-conjugated secondary antibody at a 1:5000 dilution (Cell Signaling, Beverly, MA) for 1 hour at room temperature. The bands were visualized by chemiluminescence (ECL west- ern blotting analysis system; Amersham Biosciences). Reactive oxygen species measurement Fluorescence spectrophotometry was used to measure ROS, with 2’,7’-DCF-DA as the probe (Life Technologies, Carlsbad, CA, USA). DCF-DA readily diffuses through the membrane and is enzymatically hydrolyzed by intracellular esterases to the nonfluorescent DCFH, which can then be rapidly oxidized to fluorescent DCF in the presence of ROS. PVECs incubated in the presence of CeO2NPs or vehicle were washed with PBS buffer and incubated with 10 μM DCF-DA in DMEM for 50 min at 37 ºC in the dark. The supernatant was collected to measure the extracellular production of ROS, and the intensity of fluorescence was immediately read in a fluorescence spectrophotometer (FLUOstar OPTIMA; BMG LABTECH, Ortenberg, Ger- many) at 485 nm for excitation and at 520 nm for emission. Oxidative stress present in rat portal veins was determined by malondialdehyde (MDA) assay (ELISA) according manufacturer’s instructions (Cell Biolabs, San Diego, USA). Statistical analysis Quantitative data were analyzed using GraphPad Prism, version 5 (GraphPad Software, Inc., San Diego, CA) and public libraries from The Comprehensive R Archive Network (CRAN; http://CRAN.R-project.org) rooted in the open source statistical computing environment R, version 3.4 (http://www.R-project.org/). The statistical analysis of the results was performed using unpaired Student’s t-tests and ANOVA models (with Tukey’s post hoc test) with nor- mally distributed data. For other type of data, the Mann–Whitney U-test and the Kruskal- PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 6 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Wallis tests (with Dunn post hoc test) were used. Results are expressed as mean±s.e.m and considered significant at a p value lower than 0.05. Results Generation and characterization of immortalized PVECs from portal vein of control and cirrhotic rats To investigate the cellular mechanisms that contribute to the portal vascular dysfunction char- acteristic of cirrhosis, we isolated rat portal endothelial cells (PVEC) from control and cirrhotic rats. After the immortalization procedure using middle T antigen we established two cell clones for each experimental condition. Next, cells were tested for the maintenance of endo- thelial cell markers. Freshly isolated PVEC maintained the characteristic cobblestone morphol- ogy of endothelial cells (Fig 1A, panels a and b). Immortalization resulted in altered cell shape and a lack of the directional alignment characteristic of the primary PVEC (Fig 1A, panels c and d). Despite the change in morphology, nearly 97% of immortalized iPVEC (iPVEC) con- served the expression of the endothelial cell markers CD31 and VE-cadherin, as assessed by immunofluorescence (Fig 1B), flow cytometry (Fig 1C) and western blot (Fig 1D). In the case of VE-cadherin, iPVEC from cirrhotic rats expressed lower levels of VE-cadherin compared with control rats, suggesting that these cells have maintained part of the altered phenotype caused by the cirrhosis condition. Alpha-smooth muscle actin (α-SMA) protein was undetect- able in either of the immortalized iPVEC clones established from control and cirrhotic rats (Fig 1B, panels b and e), ruling out the presence of contaminating pericytes or vascular smooth muscle cells. iPVEC and portal veins from cirrhotic rats showed a similar gene expression profile and increased levels of ROS To further investigate the possibility that iPVECs from cirrhotic rats maintained part of the altered phenotype caused by the cirrhosis condition, we measured by real-time PCR the expression of genes that were previously described to be differentially expressed in other vas- cular territories due to chronic liver disease [17,18,21,22]. All of the genes that we measured in iPVECs have known roles in inflammation (IL-6), regulation of the vascular tone and remod- eling (collagen 1, endothelin-1, MMP2, TIMP1, TIMP2 and eNOS). Col1A1, endothelin-1, MMP2, IL-6, TIMP1, TIMP2 and PlGF were differentially expressed in iPVECs from cirrhotic rats (Fig 2A). All of them except MMP2 were up-regulated in the cirrhosis condition being IL- 6 the gene showing the largest extent of up-regulation. In the case of MMP2, iPVECs from cir- rhotic rats showed a 5-fold downregulation of this gene compared with iPVECs from control rats (Fig 2A). Unexpectedly, negligible expression of eNOS was seen in the iPVECs clones obtained from control or cirrhotic rats. To study the in vivo correlation of the differential expression found in iPVECs, portal veins from control and cirrhotic rats were processed to quantify mRNA expression. The same panel of genes was measured in whole portal vein and the result was compared with that obtained in iPVECs. As shown in Fig 2B, portal vein from cirrhotic rats overexpressed collagen I, endothe- lin-1, IL-6, TIMP1, TIMP2 and PlGF. This profile of overexpressed genes is consistent with the differential expression found in iPVEC from cirrhotic rats except for MMP2, which showed opposite mRNA changes in portal vein (~4-fold overexpression) and iPVECs (~5-fold downregulation), compared with the control condition. The eNOS gene was also found to be overexpressed in the portal vein of cirrhotic rats, in agreement with what have been described in other vascular areas studied in the CCl4, BDL or PVL experimental rat models [2]. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 7 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Fig 1. Immortalized PVEC maintain endothelial cell features. PVECs were isolated from portal veins from control and cirrhotic rats. Immortalization of the cells was carried out using a retrovirus long sequence containing the SV40 virus T antigen. A Images taken by optical microscope of PVECs from control (left) and cirrhotic (right) rats, before (top) and after (bottom) immortalization, are shown. B CD31 and α-SMA immunostainings are shown for iPVECS established from control (a, b and c panels) and cirrhotic rats (d, e and f panels). The merged panels show CD31 and α-SMA colocalization. Nuclei were stained with DAPI (blue) (n = 5). Original magnification 200X. C iPVECs were immunostained for CD31 and analyzed by flow cytometer. Panel a shows dot-blot graph of the cell population. The negative population for the CD31 antigen was chosen from cells quantified in the absence of anti-CD31 antibody (panel c), CT-iPVEC (panel b), and CH-iPVEC (panel d) (n = 5). D cell lysates were analyzed by western blot. Upper panel shows VE-Cadherin immunoblot with loading control by ponceau staining. Lower panel shows densitometric analysis of the western blot. � p<0.05 vs control. https://doi.org/10.1371/journal.pone.0218716.g001 It has been established that vascular dysfunction is closely associated with elevated produc- tion of vascular ROS. For instance, oxidative stress up-regulates the expression of endothelin-1 [23], pro-inflammatory mediators such as IL-6 [24] and vascular remodeling factors such as collagen 1 [25,26], which we found overexpressed in both iPVEC and portal vein from cir- rhotic rats. Therefore, it is possible that vascular oxidative stress may be involved in the pheno- typic switch that we observed in endothelial cells from portal veins of cirrhotic rats. In order to verify this hypothesis, we investigated the production of reactive oxygen species in iPVEC from both control and cirrhotic rats. We added dihydrodichlorofluorescein diacetate (H2DCF-DA) to cells in culture to measure oxidative stress in iPVEC. H2DCF-DA accumu- lates preferentially in the cytosol and the intracellular oxidation of H2DCF into the fluoro- chrome DCF is measured to evaluate generalized oxidative stress. We compared the baseline PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 8 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Fig 2. Comparison of gene expression profiles between CT-iPVEC and CH-iPVEC. A iPVECs established from the portal vein of control (CT-iPVEC) or cirrhotic rats (CH-iPVEC) were lysed in trizol and their mRNA expression was analyzed by real-time PCR, as described in materials and methods. Graph show the different expression levels for the corresponding genes. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. � p<0.05 vs control (n = 10). B Portal veins from either control or cirrhotic rats were extracted and Lysed in Trizol. mRNA expression was analyzed by real-time PCR. Graph show the different expression levels for the corresponding genes. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. � p<0.05 vs control (n = 10). https://doi.org/10.1371/journal.pone.0218716.g002 level of oxidative stress in both groups of iPVECs. As shown in Fig 3A, DCF levels were 2-fold higher in iPVEC from cirrhotic rats compared with iPVEC isolated from control rats. Oxida- tive stress was also measured in whole portal veins from cirrhotic and control rats by malon- dialdehyde (MDA) quantification. In agreement with the ROS measurement in iPVECs, MDA levels were between 3 and 6-fold higher in portal veins from cirrhotic rats compared with por- tal veins from control rats (Fig 3B). CeO2NPs treatment reduced oxidative stress of portal vein endothelial cells in vitro and in vivo, and partially normalizes the endothelium angioarchitecture in the portal vein An important question is whether and effective anti-oxidant intervention in the portal vein may result in a normofunctional vascular reprogrammation of the transcriptome in CCl4- PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 9 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Fig 3. Increased levels of ROS in CH-PVEC and portal vein of cirrhotic rats are reduced by CeO2NPs treatment. A HR-TEM photomicrograph of CeO2NPs (400,000X). The suspension of CeO2NPs for HR-TEM was dispersed on a copper grid coated with a formvar film as described in material and methods. B oxidative stress was measured in cell lines using DCF. Graph shows the oxidation level at basal and different concentrations of CeO2NPs. � p<0.05 vs basal condition (n = 10). C oxidative stress was measured in portal veins using MDA assay. Table shows the oxidation level expressed as pmol of MDA per mg of portal vein tissue extracted from rats treated with vehicle or CeO2NPs (0.1 mg/kg) (n = 5). D CeO2NP treatment promoted angioarchitecture normalization in the portal vein of cirrhotic rats. Representative scanning electron micrographs of the vascular endothelium from portal veins of control, cirrhotic and CeO2NPs treated cirrhotic rats (X 500; 15.0 kV). Arrows denote high profusion of endothelial exfoliation with loss of cell-cell junctions. Arrow heads denote extra-vascular cell adhesion to the vascular endothelium (n = 3). https://doi.org/10.1371/journal.pone.0218716.g003 treated rats. With this objective in mind we treated iPVEC and cirrhotic animals with the nanomaterial cerium oxide. Fig 3C shows the transmission electron microscopy (TEM) images of the CeO2NPs suspension, which is characterized by a similar polyhedral shape of the nano- particles with loose agglomerates and an average diameter of 4–20 nm. The antioxidant activity of CeO2NPs was assessed on iPVECs by measuring the intracellular accumulation of DCF. CeO2NPs tested in the dose range 0.1–10 μg/mL did not appear to pro- duce any change on DCF values in iPVEC from control rats, suggesting that the baseline levels of ROS in the iPVECs from control rats are negligible. In contrast, CeO2NPs treatment of cir- rhotic iPVEC reduces significantly the intracellular levels of ROS at the doses from 1 to 3 μg/ mL. Specifically, CeO2NPs showed the highest scavenging activity at a concentration of 1 μg/ mL. At this optimal concentration, DCF fluorescence significantly decreased, approaching the levels found in control iPVECs. However, cirrhotic iPVECs exposed to CeO2NPs at higher PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 10 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats doses than 3 μg/mL showed a hormetic-like dose response characterized by an increasing-dose inefficacy in ROS scavenging (Fig 3A). The direct toxic effect of CeO2NPs on iPVECs was also evaluated with the Trypan Blue exclusion test. At the concentration tested (0.1–10 μg/mL), the exposure of the cells with the nanoparticles did not affect cell viability. To translate our in vitro results to the in vivo situation, we investigate whether portal vein from cirrhotic rats reduced its oxidative stress levels in response to the chronic treatment with CeO2NPs. After 2 weeks of CeO2NPs treatment, portal veins from both control and cirrhotic rats retained a 7% of the total dose of nanoparticles given via tail vein injection, as measured by inductively coupled plasma mass spectrometry (14.26 μg from the total 200 μg CeO2NPs administered over the two-week treatment period). After the treatment, we measured the lev- els of MDA in the portal vein from cirrhotic rats treated with CeO2NPs and we found that the levels were negligible compared with portal vein from cirrhotic rats without treatment (Fig 3B, last row). These findings correlated with an improvement of the endothelium monolayer in the portal vein. Under scanning electron microscope (SEM), cirrhotic portal vein presents a rougher and unstructured surface (Fig 3D, panel b), while these abnormalities were partially corrected after the chronic treatment with CeO2NPs resulting in a smoother surface (Fig 3D, panel c), more similar to the control condition (Fig 3D, panel a). Conditioned medium from CH-iPVEC polarized macrophages to an M1 phenotype The interaction between the endothelium and leukocytes is critical for the activation and the recruitment of inflammatory cells. We have found that iPVEC from cirrhotic rats overex- pressed IL-6. Considering this proinflammatory phenotype, we next investigated whether the secretome of iPVECs from cirrhotic rats affected macrophage polarization and, therefore, inflammatory response. For this purpose, we collected conditioned medium of iPVEC from control and cirrhotic rats that were cultivated in presence of 2%FBS for 72 hours. The iPVEC secretomes from each cell clone isolated from the control and the cirrhosis condition were characterized by proteomics (SELDI-TOF mass spectrometry). As shown in Fig 4A, eight peptidic clusters from the collected conditioned medium of the two CH-iPVEC clones showed a significant higher intensity (m/z of 7.530, 7.715, 7.810, 7.915, 7.990, 8.010, 8.320 and 8.480 kDa), while 2 peaks (m/z of 7.500 and 8.515 kDa) showed a lower intensity when com- pared with the CT-iPVEC conditioned media. This divergence in the secretomes of iPVEC suggests that besides presenting a differential transcription reprogramming, iPVECs from cir- rhotic rats may also interact differentially with their cellular environment through their secretome. To determine the effect of iPVECs on macrophage polarization, we exposed bone marrow derived macrophages to conditioned medium from CT-iPVEC or CH-iPVEC for 8h. Without any additional stimuli, conditioned medium from CH-iPVEC induced the expression of iNOS and TNF-α in macrophages and downregulated arginase-1 (Arg-1) mRNA, compared with conditioned medium from CT-iPVEC (Fig 4B). To investigate further the effect of iPVEC on macrophage polarization induced by the cytokine environment, we characterized the effect of conditional medium on the induction of M1 and M2 polarization by IFN-γ and IL-4, respec- tively. As shown in Fig 4C, CH-iPVEC conditioned medium potentiates the effect of IFN-γ on the induction of iNOS and TNF-α overexpression in macrophages. Consistently, we found that macrophages exposed to CH-iPVEC showed a significant downregulation of arginase-1 mRNA after incubation with IL-4, compared with the CT-iPVEC treatment. These results together, demonstrate the ability of the CH-iPVEC secretome to polarize macrophages toward the M1 fate in both basal conditions and after cytokine stimulation. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 11 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Fig 4. Characterization of iPVEC secretome and iPVEC-induced macrophage polarization. A Representative proteomic profile of conditioned cell culture media (DMEM supplemented with 2% FBS) obtained from CT-PVEC (blue spectrogram) and CH-PVEC (red spectrogram) after 3 days of cell culture. Graph shows a differential proteomic signature in the segment of the SELDI-TOF-MS spectra PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 12 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats ranging from m/z 7,2 kDa to m/z 8,6 kDa (n = 3). B Bone marrow derived macrophages (BMDM) were incubated with conditioned medium from either CT-PVEC (CT-CM) or CH-PVEC (CH-CM). Panel shows gene expression levels for the different genes analyzed. mRNA levels are illustrated as fold change relative to HPRT mRNA levels � p<0.01 vs CT-CM (n = 10). C BMDM were incubated with CT-CM or CH-CM and simultaneously with either IL-4 or IFN-γ for 8h (10ng/mL). Panels show iNOS and TNF-α gene expression after IFN-γ treatment and arginase-1 (Arg1) after IL-4 treatment. � p<0.01 vs. CT-CM, #p<0.01 vs. CT-CM treated with IL-4 or INF-γ (n = 10). https://doi.org/10.1371/journal.pone.0218716.g004 CeO2NPs treatment switch CH-iPVEC-induced macrophage polarization from M1 to M2 Once we established the optimal concentration for CeO2NPs treatment, we next investigated whether the protection against oxidative stress in iPVEC improves the altered gene expression pattern that we previously described in the cirrhotic condition. The treatment of iPVECs with 1μg/mL CeO2NPs for 24 hours did not modify the expression of Col1A1, endothelin-1, TIMP1, PlGF or MMP2; compared with vehicle treatment (S1 Fig). Interestingly, CeO2NPs treatment caused a significant decrease in the expression of IL-6 and TIMP-2 in CH-iPVEC, suggesting that oxidative stress is mediating the overexpression of these genes (Fig 5A). Next, we also investigate the effect of CeO2NPs on iPVEC-induced macrophage polariza- tion. iPVEC were incubated with CeO2NPs for 24h. After medium removal, cells were placed in DMEM supplemented with 2% FCS for three additional days. Conditioned medium from CH-iPVEC treated with CeO2NPs significantly increased the levels of arginase-1 on macro- phages in response to IL-4 treatment, compared with CH-iPVEC treated with vehicle (Fig 5B, top graph). Additionally, CeO2NPs treatment blocked iNOS overexpression induced by CH- iPVEC conditioned medium to a similar level to that obtained by the CT-iPVEC condition upon IFN-γ stimulation (Fig 5B, bottom graph). Therefore, CeO2NPs treatment potentiates macrophage M2 polarization through changes on the CH-iPVEC secretome. Cirrhotic rats treated chronically with CeO2NPs down-regulated IL-6 expression in portal vein As showed above, CeO2NP treatment can modify the expression of certain genes in iPVECs in vitro. Therefore, we next assessed whether the chronic treatment of rats with CeO2NPs also has an effect on the portal vein through the modification of its gene expression pattern. To this aim, we quantified the expression of the same genes that were differentially expressed in CH- iPVECs after CeO2NPs treatment, IL-6 and TIMP-2. As shown in Fig 5C (right graph), TIMP- 2 showed similar expression levels in the portal vein of control and cirrhotic rats regardless of the CeO2NPs treatment. Interestingly and in agreement with the in vitro experiments, the treatment of cirrhotic rats with CeO2NPs significantly downregulated IL-6 in portal vein, com- pared with vehicle treated rats (Fig 5C, left graph). These results demonstrated the in vivo util- ity of CeO2NPs treatment for modulating the pathological phenotype of the vasculature in chronic liver disease. Discussion Our results describe for the first time that the endothelium of the portal vein from cirrhotic rats has pro-inflammatory properties, which are the overexpression of IL-6 and the induction of M1 macrophage polarization. We showed that an excess of ROS is responsible of this vascu- lar alteration associated with cirrhosis because the treatment with the CeO2 antioxidant nano- particles reverts this pro-inflammatory phenotype. The term ROS includes free radicals and strong oxidants such as superoxide anion radical (�O2-), hydroxyl radical (HO�), hydrogen peroxide (H2O2) and hypochlorous acid (HOCl), all of them being highly reactive. When ROS levels exceed cellular antioxidant defenses oxidative PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 13 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Fig 5. CeO2NPs treatment modified the altered gene expression pattern of CH-PVEC and portal vein from cirrhotic rats and potentiates macrophage M2 polarization. A CT-iPVECs and CH-iPVECs were incubated with vehicle or 1μg/mL CeO2NPs for 24h. Cells were lysed in trizol and mRNA levels of IL-6 (left graph) and TIMP2 (right graph) were quantified by real-time PCR. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. � p<0.05 vs CH-PVEC without CeO2NPs (n = 5). B BMDM were incubated with CT-CM or CH-CM from iPVEC treated with CeO2NPs (1μg/mL) for 24h or vehicle and stimulated simultaneously with either IL-4 or IFN-γ 10ng/mL for 8h. Top graph shows arginase-1 gene expression after IL-4 stimulation and bottom graph shows iNOS gene PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 14 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats expression after IFN-γ stimulation. mRNA levels are illustrated as fold change relative to HPRT mRNA levels. � p<0.05 vs. their corresponding CeO2NPs-untreated control groups (n = 10). C Portal veins from either control or cirrhotic rats treated i.v. with vehicle or 0.1 mg/kg CeO2NPs for 2 weeks were extracted and lysed in trizol. mRNA expression was analyzed by real-time PCR and represented as fold change relative to HPRT mRNA levels. � p<0.05 vs. its corresponding CeO2NPs-untreated control group (n = 5). https://doi.org/10.1371/journal.pone.0218716.g005 damage develops within the cells promoting molecular damage in DNA, lipids and proteins. The presence of oxidative stress has been described in most of the clinical conditions associ- ated with liver fibrosis and portal hypertension as well as in experimental models of liver injury (NASH, HCV, alcoholic liver cirrhosis, hemochromatosis, Wilson’s disease, primary biliary cirrhosis, cholestasis, cirrhosis induced by CCl4 in rodents, and bile duct ligation in rodents). Concurrently, the association between high levels of oxidative stress and a reduction of antiox- idant defenses has also been reported in the same or similar pathological situations [27,28]. Several strategies have been investigated to diminish ROS damage such as the transduction of the liver of cirrhotic rats with adenovirus encoding for SOD, which resulted in a significant improvement of portal pressure [29]. In the same experimental model, hesperidin -an antioxi- dant bioflavonoid- also ameliorates liver damage through the inhibition of oxidative stress [30]. In addition, Bataller et al. demonstrated that NADPH oxidase is present in activated HSCs and generate ROS in an angiotensin II dependent way. The link between NADPH oxi- dase activity and fibrosis was further demonstrated in vivo in mice lacking a functional NADPH oxidase [31]. All these studies highlight the need of targeting hepatic oxidative stress in cirrhotic livers. However, studies investigating the pathological role plaid by ROS in the por- tal vein of patients or animal models with chronic liver disease are still lacking. In other pathological contexts, several authors have described the vascular endothelium as one of the most sensitive targets for oxidative stress. Endothelial activation caused by ROS exposure is a feature of several dysfunctions including diabetes, vascular toxicity, hypertension, ischemia, inflammation, acute and chronic tissue injury, atherosclerosis and hypertension [32–35]. Some of the genes modulated by ROS in these disease scenarios are endothelin-1 [23], pro-inflammatory mediators such as IL-6 [24] and vascular remodeling factors such as colla- gen 1 [25,26]. In agreement with these studies, we found these genes overexpressed in portal vein from cirrhotic rats together with MMP-2, TIMP-1, TIMP-2 and PlGF. The expression profile found in the immortalized PVECs from cirrhotic rats was quantitatively similar com- pared to whole portal vein tissue. The only difference was found in the expression of the MMP-2 gene, which was decreased in CH-PVEC, compared to CT-PVEC. This discrepancy could be attributed to the fact that whole portal vein extracts contain mRNA from other cell types, apart from endothelial cells, that may contribute to the overall mRNA expression differ- ences. Despite this punctual difference, the use of iPVECs in our study has proven to be useful for the study of the portal vein abnormalities occurring in cirrhosis and, additionally, may pro- vide us with basic scientific understanding of the mechanism leading to endothelial activation. For instance, the similarity found when comparing the iPVECs and the portal vein transcrip- tomes suggests that there may be an epigenetic component that maintains the differential expression despite the elevated number of cellular passages needed to generate the immortal- ized PVECs. Yet being a suggestive hypothesis, we need further investigation to confirm this link. As a downside of using the iPVECs cell line, we have observed negligible eNOS gene expression in all the cellular clones established. This phenomenon has previously described by others in the context of later culture passages of endothelial cells [36]. Therefore, and despite that the iPVECs still conserved other endothelial cells markers, some endothelial functions may be lost in the iPVECS. This drawback should be kept in mind when interpreting the data obtained in this cellular model of portal vein endothelium. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 15 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats CeO2NP has caught considerable attention as a potential therapeutic tool in the prevention and treatment of oxidative stress related diseases. This interest relies on the expected properties of this nanomaterial to scavenge most of the ROS due to its multi-enzyme mimetic activities that resemble the mechanism of SOD, catalase and peroxidase enzymes [37,38]. The beneficial effects of CeO2 treatment have been reported in the fields of neurology [39–41], diabetes [42,43], retinal diseases [44,45], chronic inflammation [38,46], gastrointestinal epithelium inflammation [47], hepatoprotection against monocrotaline [48], liver cirrhosis [20] and cancer [47,49]. Consistently with these publications, we demonstrated that CeO2NPs treatment was effec- tive in reducing the proinflammatory state of endothelial cells from the portal vein of cirrhotic rats. The main feature of this beneficial effect was the downregulation of IL-6 expression in both cultured PVEC and portal vein from cirrhotic rats. The similar responses observed in the in vitro studies with isolated endothelial cells and the in vivo models seem to indicate of the efficient targeting of the CeO2NPs to the cells of interest after i.v. administration. One of the potential explanations of these results is that the structural alterations in blood vessels occur- ring during inflammation enhanced CeO2NPs vascular uptake. Increased ROS contribute to vascular injury by promoting abnormal vascular cell growth, disruption of inner endothelial cell monolayer integrity and extracellular matrix remodelling [50,51]. These vascular abnor- malities can be summarized as an increased roughness of the inner vascular layer, loss of the cobblestone endothelial structure and increased extracellular cell adhesion to the vasculature, in contrast to the uniform endothelial lining characteristic of the portal vein from control rats. Interestingly, the treatment of cirrhotic rats with CeO2NPs resulted in the correction of these morphological alterations. Despite that CeO2NPs flow modes in the blood stream are still a subject of debate [52,53], it is reasonable to hypothesize that CeO2NPs will be preferentially retained in rough and porous surfaces rather than in smooth and tight ones, promoting thus the passive targeting of CeO2NPs in the region of interest. Many studies have reported high levels of the proinflammatory cytokine IL-6 in experimen- tal models and patients with liver cirrhosis [54–58]. In addition, it has been proposed a link between high concentration of IL-6 and HCC [59,60]. Therefore, it is conceivable that the anti-inflammatory phenotype caused by CeO2 in the portal vein of cirrhotic rats could contrib- ute to an improvement in liver function. We characterized further this anti-inflammatory effect by studying the polarization of the macrophages when they interact with CT-iPVECs or CH-iPVECs. The current model of macrophage polarization proposes two major populations of macrophages: M1 macrophages, which produce proinflammatory cytokines, ROS, which are prominently proinflammatory, and M2 macrophages, which promote tissue repair and stimulate vascular growth. M1-polarized macrophages express IL-1, TNF, IL-6, IL-12, IL-23, and iNOS in response to INF-γ; whereas M2 macrophages express IL-10, Decoy IL-1RII, IL- 1ra and arginase in response to IL4. We showed that macrophages incubated with conditioned medium from CH-iPVEC were skewed to an M1 phenotype. In addition, the stimulation of macrophages with either IFN-γ or IL4 in the presence of conditioned medium from CH-PVEC potentiated M1 polarization and inhibited M2 polarization, respectively. Noteworthy, CH- iPVECs pre-treated with CeO2NPs lost their ability to potentiate M1 polarization while pro- moting a M2-like phenotype in macrophages. The implications of these results are encourag- ing. For instance, it has recently been reported that fibrosis improves with the injection of BM- derived macrophages. However it has not been determined whether macrophage polarization could influence the outcome of this treatment [55]. Therefore, it is reasonable to speculate that an anti-inflammatory/remodeling phenotype of therapeutic macrophages would be beneficial, given that exacerbated inflammation contributes to the perpetuation of liver damage. In this context, the results of our study suggest that the combination of CeO2NPs with cell therapy is worth to evaluate in the context of chronic liver diseases. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 16 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Some of the advantages of using CeO2 nanomaterials over the traditional antioxidative drugs are: 1) the multi-enzyme mimetic activities of CeO2NPs, which targets several sources of ROS generation and 2) the continuous regeneration of the CeO2NPs catalytic activity, which avoids the exhaustion of its anti-oxidative properties [61]. However, a big effort in standardiza- tion is still needed for the field to progress. In contrast to the soluble drugs used in clinics for which optimal dosages are determined in traditional toxicology studies, the therapeutic effi- cacy of the CeO2NPs does not depend exclusively of the dose. We should also consider other properties such as shape, density, surface area, size and physical-chemical properties of the nanoparticle in solution. Changes in these features may affect the catalytic activity and solubil- ity of the nanoparticle [62,63]. Therefore, these parameters have to be properly tuned and stan- dardized among different laboratories before this therapeutic strategy can be translated into the clinical area. Supporting information S1 Fig. Characterization of CH-PVEC gene expression pattern after CeO2NPs treatment. CT-iPVECs and CH-iPVECs were incubated with vehicle or 1μg/mL CeO2NPs for 24h. Cells were lysed in trizol and mRNA levels of Col1A1, endothelin-1, TIMP1, PlGF and MMP2, were quantified by real-time PCR. mRNA levels are illustrated as fold change relative to HPRT mRNA levels (n = 5). (TIF) S1 File. Gel raw images. VE-Cadherin gel raw images: upper image shows VE-Cadherin west- ern blot and lower image the ponceau staining. (TIF) S2 File. ARRIVE Guidelines checklist. Document that aims to improve experimental report- ing and reproducibility of animal studies for purposes of post-publication data analysis and reproducibility. (PDF) Acknowledgments The retroviral vector codifying for the middle T antigen from the SV40 virus was kindly pro- vided by Dr. William C. Sessa, Yale University School of Medicine, New Haven. Author Contributions Conceptualization: Juan Rodrı́guez-Vita, Gregori Casals, Eudald Casals, Wladimiro Jiménez, Victor Puntes, Manuel Morales-Ruiz. Data curation: Juan Rodrı́guez-Vita, Victor Puntes, Manuel Morales-Ruiz. Formal analysis: Jordi Ribera, Juan Rodrı́guez-Vita. Funding acquisition: Manuel Morales-Ruiz. Investigation: Jordi Ribera, Juan Rodrı́guez-Vita, Eudald Casals, Victor Puntes, Manuel Morales-Ruiz. Methodology: Jordi Ribera, Bernat Cordoba, Irene Portolés, Eudald Casals. Project administration: Manuel Morales-Ruiz. Supervision: Manuel Morales-Ruiz. PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 17 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats Validation: Manuel Morales-Ruiz. Writing – original draft: Victor Puntes, Manuel Morales-Ruiz. Writing – review & editing: Jordi Ribera, Juan Rodrı́guez-Vita, Gregori Casals, Wladimiro Jiménez. References 1. Geller DA, Goss JA, Tsung A. Liver. In: Brunicardi FC, Andersen DK, Billiar TR, Dunn DL, Hubter JG, Matthews JB, et al., editors. Principles of Surgery, 9 ed. New York: McGraw-Hill Professional; 2009. p. 1–42. 2. Morales-Ruiz M, Rodrı́guez-Vita J, Ribera J, Jiménez W. Pathophysiology of Portal Hypertension. Pan- Vascular Medicine. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. pp. 3631–3665. https://doi. org/10.1007/978-3-642-37078-6_144 3. Sarin S.K., Wadhawan M. Noncirrhotic portal hypertension and portal vein thrombosis. In: Sanyal AJ, Shah VH, editors. Portal Hypertension. Pathobiology, Evaluation, and Treatment, 1 ed. Totowa, NJ: Humana Press; 2005. p. 411–432. https://doi.org/10.1007/978-1-59259-885-4_25 4. Shah VH, Kamath PS. Portal Hypertension and Gastrointestinal Bleeding. In: Feldman M, Friedman LS, editors. Gastrointestinal and liver disease: Pathophysiology, Diagnosis, Management, 9 ed. Phila- delphia, PA: Saunders; 2010. p. 1489–1516. 5. Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology. 2004; 39: 280–2. https://doi.org/10.1002/hep.20062 PMID: 14767976 6. Wongcharatrawee S, Groszmann RJ. Diagnosing portal hypertension. Baillieres Best Pract Res Clin Gastroenterol. 2000; 14: 881–94. https://doi.org/10.1053/bega.2000.0136 PMID: 11139344 7. Bevilacqua MP, Pober JS, Mendrick DL, Cotran RS, Gimbrone MA Jr. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc Natl Acad Sci U S A. National Academy of Sciences; 1987; 84: 9238–42. 8. Gamble JR, Harlan JM, Klebanoff SJ, Vadas MA. Stimulation of the adherence of neutrophils to umbili- cal vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci U S A. National Academy of Sciences; 1985; 82: 8667–71. 9. Gimbrone MA, Garcı́a-Cardeña G. Vascular endothelium, hemodynamics, and the pathobiology of ath- erosclerosis. Cardiovasc Pathol. 2013; 22: 9–15. https://doi.org/10.1016/j.carpath.2012.06.006 PMID: 22818581 10. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expres- sion of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol. 1986; 136: 1680–7. PMID: 3485132 11. Schleimer RP, Rutledge BK. Cultured human vascular endothelial cells acquire adhesiveness for neu- trophils after stimulation with interleukin 1, endotoxin, and tumor-promoting phorbol diesters. J Immunol. 1986; 136: 649–54. PMID: 2416819 12. Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia-Pagan JC, Bosch J. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology. 2007; 46: 1208–1217. https://doi.org/ 10.1002/hep.21785 PMID: 17654489 13. Guidotti LG, Inverso D, Sironi L, Di Lucia P, Fioravanti J, Ganzer L, et al. Immunosurveillance of the Liver by Intravascular Effector CD8+ T Cells. Cell. 2015; 161: 486–500. https://doi.org/10.1016/j.cell. 2015.03.005 PMID: 25892224 14. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology. 1998; 28: 926–931. https:// doi.org/10.1002/hep.510280405 PMID: 9755227 15. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005; 11: 952–8. https://doi.org/10. 1038/nm1289 PMID: 16142243 16. Tugues S, Fernandez-Varo G, Muñoz-Luque J, Ros J, Arroyo V, Rodés J, et al. Antiangiogenic treat- ment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology. 2007; 46: 1919–26. https://doi.org/10.1002/hep.21921 PMID: 17935226 PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 18 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats 17. Steenkiste C Van, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology. 2011; 53: 1629–1640. https://doi.org/10.1002/hep.24238 PMID: 21520176 18. Tugues S, Morales-Ruiz M, Fernandez-Varo G, Ros J, Arteta D, Muñoz-Luque J, et al. Microarray anal- ysis of endothelial differentially expressed genes in liver of cirrhotic rats. Gastroenterology. 2005; 129: 1686–1695. https://doi.org/10.1053/j.gastro.2005.09.006 PMID: 16285966 19. Cafun JD, Kvashnina KO, Casals E, Puntes VF, Glatzel P. Absence of Ce3+ sites in chemically active colloidal ceria nanoparticles. ACS Nano. 2013; 7: 10726–32. https://doi.org/10.1021/nn403542p PMID: 24215500 20. Oró D, Yudina T, Fernández-Varo G, Casals E, Reichenbach V, Casals G, et al. Cerium oxide nanopar- ticles reduce steatosis, portal hypertension and display anti-inflammatory properties in rats with liver fibrosis. J Hepatol. 2016; 64: 691–8. https://doi.org/10.1016/j.jhep.2015.10.020 PMID: 26519601 21. Leivas A, Jiménez W, Lamas S, Bosch-Marcé M, Oriola J, Clària J, et al. Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites. Gastroenterology. 1995; 108: 1842–8. PMID: 7768391 22. Fernández-Varo G, Morales-Ruiz M, Ros J, Tugues S, Muñoz-Luque J, Casals G, et al. Impaired extra- cellular matrix degradation in aortic vessels of cirrhotic rats. J Hepatol. 2007; 46: 440–446. https://doi. org/10.1016/j.jhep.2006.09.023 PMID: 17156884 23. Koh KK, Oh PC, Quon MJ. Does reversal of oxidative stress and inflammation provide vascular protec- tion? Cardiovasc Res. 2008; 81: 649–659. https://doi.org/10.1093/cvr/cvn354 PMID: 19098298 24. Lee P-C, Ho I-C, Lee T-C. Oxidative stress mediates sodium arsenite-induced expression of heme oxy- genase-1, monocyte chemoattractant protein-1, and interleukin-6 in vascular smooth muscle cells. Toxi- col Sci. Oxford University Press; 2005; 85: 541–50. https://doi.org/10.1093/toxsci/kfi101 PMID: 15689417 25. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005; 25: 29–38. https://doi.org/10.1161/01.ATV.0000150649.39934.13 PMID: 15539615 26. Grossman E. Does Increased Oxidative Stress Cause Hypertension? Diabetes Care. 2008; 31: S185– S189. https://doi.org/10.2337/dc08-s246 PMID: 18227483 27. Colell A, Garcı́a-Ruiz C, Miranda M, Ardite E, Marı́ M, Morales A, et al. Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology. 1998; 115: 1541–51. PMID: 9834283 28. Simeonova PP, Gallucci RM, Hulderman T, Wilson R, Kommineni C, Rao M, et al. The Role of Tumor Necrosis Factor-α in Liver Toxicity, Inflammation, and Fibrosis Induced by Carbon Tetrachloride. Toxi- col Appl Pharmacol. 2001; 177: 112–120. https://doi.org/10.1006/taap.2001.9304 PMID: 11740910 29. Lavina B, Gracia-Sancho J, Rodriguez-Vilarrupla A, Chu Y, Heistad DD, Bosch J, et al. Superoxide dis- mutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. Gut. 2009; 58: 118–125. https://doi.org/10.1136/gut.2008.149880 PMID: 18829979 30. Tirkey N, Pilkhwal S, Kuhad A, Chopra K. Hesperidin, a citrus bioflavonoid, decreases the oxidative stress produced by carbon tetrachloride in rat liver and kidney. BMC Pharmacol. 2005; 5: 2. https://doi. org/10.1186/1471-2210-5-2 PMID: 15683547 31. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal trans- duces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest. 2003; 112: 1383–1394. https://doi.org/10.1172/JCI18212 PMID: 14597764 32. Praticò D. Antioxidants and endothelium protection. Atherosclerosis. 2005; 181: 215–24. https://doi. org/10.1016/j.atherosclerosis.2005.03.005 PMID: 15893757 33. McCord JM, Roy RS, Schaffer SW. Free radicals and myocardial ischemia. The role of xanthine oxi- dase. Adv Myocardiol. 1985; 5: 183–9. PMID: 2982206 34. Salonen JT, Seppänen K, Lakka TA, Salonen R, Kaplan GA. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis. 2000; 148: 265–73. https://doi.org/10.1016/S0021-9150(99)00272-5 PMID: 10657561 35. Touyz RM. Reactive Oxygen Species, Vascular Oxidative Stress, and Redox Signaling in Hyperten- sion: What Is the Clinical Significance? Hypertension. 2004; 44: 248–252. https://doi.org/10.1161/01. HYP.0000138070.47616.9d PMID: 15262903 36. Shi Q, Aida K, Vandeberg JL, Wang XL. Passage-dependent changes in baboon endothelial cells—rel- evance to in vitro aging. DNA Cell Biol. NIH Public Access; 2004; 23: 502–9. https://doi.org/10.1089/ 1044549041562294 PMID: 15307953 37. Caputo F, De Nicola M, Ghibelli L. Pharmacological potential of bioactive engineered nanomaterials. Biochem Pharmacol. 2014; 92: 112–130. https://doi.org/10.1016/j.bcp.2014.08.015 PMID: 25175739 PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 19 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats 38. Niu J, Azfer A, Rogers LM, Wang X, Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparti- cles in a transgenic murine model of cardiomyopathy. Cardiovasc Res. 2007; 73: 549–59. https://doi. org/10.1016/j.cardiores.2006.11.031 PMID: 17207782 39. Schubert D, Dargusch R, Raitano J, Chan S-W. Cerium and yttrium oxide nanoparticles are neuropro- tective. Biochem Biophys Res Commun. 2006; 342: 86–91. https://doi.org/10.1016/j.bbrc.2006.01.129 PMID: 16480682 40. D’Angelo B, Santucci S, Benedetti E, Di Loreto S, Phani R, Falone S, et al. Cerium Oxide Nanoparticles Trigger Neuronal Survival in a Human Alzheimer Disease Model By Modulating BDNF Pathway. Curr Nanosci. 2009; 5: 167–176. https://doi.org/10.2174/157341309788185523 41. Kim CK, Kim T, Choi I-Y, Soh M, Kim D, Kim Y-J, et al. Ceria nanoparticles that can protect against ischemic stroke. Angew Chem Int Ed Engl. 2012; 51: 11039–43. https://doi.org/10.1002/anie. 201203780 PMID: 22968916 42. Pourkhalili N, Hosseini A, Nili-Ahmadabadi A, Rahimifard M, Navaei-Nigjeh M, Hassani S, et al. Improvement of isolated rat pancreatic islets function by combination of cerium oxide nanoparticles/ sodium selenite through reduction of oxidative stress. Toxicol Mech Methods. 2012; 22: 476–482. https://doi.org/10.3109/15376516.2012.673093 PMID: 22409398 43. Pourkhalili N, Hosseini A, Nili-Ahmadabadi A, Hassani S, Pakzad M, Baeeri M, et al. Biochemical and cellular evidence of the benefit of a combination of cerium oxide nanoparticles and selenium to diabetic rats. World J Diabetes. 2011; 2: 204–10. https://doi.org/10.4239/wjd.v2.i11.204 PMID: 22087357 44. Chen J, Patil S, Seal S, McGinnis JF. Rare earth nanoparticles prevent retinal degeneration induced by intracellular peroxides: Nat Nanotechnol. 2006; 1: 142–150. https://doi.org/10.1038/nnano.2006.91 PMID: 18654167 45. Zhou X, Wong LL, Karakoti AS, Seal S, McGinnis JF. Nanoceria Inhibit the Development and Promote the Regression of Pathologic Retinal Neovascularization in the Vldlr Knockout Mouse. Emanueli C, edi- tor. PLoS One. 2011; 6: e16733. https://doi.org/10.1371/journal.pone.0016733 PMID: 21364932 46. Niu J, Wang K, Kolattukudy PE. Cerium Oxide Nanoparticles Inhibits Oxidative Stress and Nuclear Fac- tor- B Activation in H9c2 Cardiomyocytes Exposed to Cigarette Smoke Extract. J Pharmacol Exp Ther. 2011; 338: 53–61. https://doi.org/10.1124/jpet.111.179978 PMID: 21464334 47. Colon J, Hsieh N, Ferguson A, Kupelian P, Seal S, Jenkins DW, et al. Cerium oxide nanoparticles pro- tect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. Nanomedicine Nanotechnology, Biol Med. 2010; 6: 698– 705. https://doi.org/10.1016/j.nano.2010.01.010 PMID: 20172051 48. Amin KA, Hassan MS, Awad E-ST, Hashem KS. The protective effects of cerium oxide nanoparticles against hepatic oxidative damage induced by monocrotaline. Int J Nanomedicine. 2011; 6: 143–149. https://doi.org/10.2147/IJN.S15308 PMID: 21289991 49. Alili L, Sack M, Karakoti AS, Teuber S, Puschmann K, Hirst SM, et al. Combined cytotoxic and anti-inva- sive properties of redox-active nanoparticles in tumor–stroma interactions. Biomaterials. 2011; 32: 2918–2929. https://doi.org/10.1016/j.biomaterials.2010.12.056 PMID: 21269688 50. Adam SK, Das S, Jaarin K. A detailed microscopic study of the changes in the aorta of experimental model of postmenopausal rats fed with repeatedly heated palm oil. Int J Exp Pathol. 2009; 90: 321–327. https://doi.org/10.1111/j.1365-2613.2009.00658.x PMID: 19563614 51. Xu S, Touyz RM. Reactive oxygen species and vascular remodelling in hypertension: still alive. Can J Cardiol. 2006; 22: 947–951. https://doi.org/10.1016/s0828-282x(06)70314-2 PMID: 16971980 52. Fullstone G, Wood J, Holcombe M, Battaglia G. Modelling the Transport of Nanoparticles under Blood Flow using an Agent-based Approach. Sci Rep. 2015; 5: 10649. https://doi.org/10.1038/srep10649 PMID: 26058969 53. Tan J, Shah S, Thomas A, Ou-Yang HD, Liu Y. The influence of size, shape and vessel geometry on nanoparticle distribution. Microfluid Nanofluidics. 2013; 14: 77–87. https://doi.org/10.1007/s10404-012- 1024-5 PMID: 23554583 54. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. Hepatology. 2006; 43: S121–S131. https://doi.org/10.1002/hep.20993 PMID: 16447289 55. Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S, et al. Macrophage ther- apy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function. Hepatology. 2011; 53: 2003–2015. https://doi.org/10.1002/hep.24315 PMID: 21433043 56. Di Pascoli M, Divı́ M, Rodrı́guez-Vilarrupla A, Rosado E, Gracia-Sancho J, Vilaseca M, et al. Resvera- trol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cir- rhotic rats. J Hepatol. 2013; 58: 904–910. https://doi.org/10.1016/j.jhep.2012.12.012 PMID: 23262250 57. Koek GH, Liedorp PR, Bast A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta. 2011; 412: 1297–1305. https://doi.org/10.1016/j.cca.2011.04.013 PMID: 21514287 PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 20 / 21 Cerium oxide nanoparticles mitigate the oxidative stress and inflammation of the portal vein in cirrhotic rats 58. Soresi M, Giannitrapani L, D’Antona F, Florena A-M, La Spada E, Terranova A, et al. Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol. 2006; 12: 2563–8. https://doi.org/10.3748/wjg.v12.i16.2563 PMID: 16688802 59. Giannitrapani L, Cervello M, Soresi M, Notarbartolo M, La Rosa M, Virruso L, et al. Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma. Ann N Y Acad Sci. 2002; 963: 46–52. https://doi.org/ 10.1111/j.1749-6632.2002.tb04093.x PMID: 12095927 60. Porta C, De Amici M, Quaglini S, Paglino C, Tagliani F, Boncimino A, et al. Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol Off J Eur Soc Med Oncol. 2008; 19: 353–8. https://doi.org/10.1093/annonc/mdm448 PMID: 17962206 61. Xu C, Qu X. Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications. NPG Asia Mater. 2014; 6: e90. https://doi.org/10.1038/am.2013.88 62. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry consid- erations for in vitro nanoparticle toxicity assessments. Toxicol Sci. 2007; 95: 300–12. https://doi.org/10. 1093/toxsci/kfl165 PMID: 17098817 63. Cho EC, Zhang Q, Xia Y. The effect of sedimentation and diffusion on cellular uptake of gold nanoparti- cles. Nat Nanotechnol. 2011; 6: 385–391. https://doi.org/10.1038/nnano.2011.58 PMID: 21516092 PLOS ONE | https://doi.org/10.1371/journal.pone.0218716 June 24, 2019 21 / 21